Zacks Investment Research Lowers Halyard Health Inc. (HYH) to Sell
Halyard Health Inc. (NYSE:HYH) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Tuesday.
According to Zacks, “Halyard Health, Inc. is a medical technology company. It is focused on advancing health and healthcare by preventing infection, eliminating pain and speeding recovery. The Company sells surgical and infection prevention products for the operating room. Halyard offers products such as sterilization wraps, face masks, surgical drapes and gowns, closed suction catheters, pain pumps and enteral feeding tubes. It offers a range of medical device solutions including post-operative pain management solutions, minimally invasive interventional (or chronic) pain therapies, closed airway suction systems, and enteral feeding tubes. Halyard Health, Inc. is headquartered in Alpharetta, Georgia. “
Other equities research analysts have also issued research reports about the company. Stifel Nicolaus upped their price objective on Halyard Health from $32.00 to $37.00 and gave the stock a “buy” rating in a research report on Tuesday, June 14th. Deutsche Bank AG upped their price objective on Halyard Health from $36.00 to $41.00 and gave the stock a “buy” rating in a research report on Wednesday, August 10th. Finally, TheStreet upgraded Halyard Health from a “sell” rating to a “hold” rating in a research report on Friday, July 8th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $34.20.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/11/zacks-investment-research-lowers-halyard-health-inc-hyh-to-sell.html
Shares of Halyard Health (NYSE:HYH) traded down 1.59% during midday trading on Tuesday, reaching $33.99. 519,426 shares of the company traded hands. The stock has a 50 day moving average price of $35.11 and a 200 day moving average price of $32.79. Halyard Health has a 1-year low of $22.76 and a 1-year high of $37.31. The firm’s market capitalization is $1.59 billion.
Halyard Health (NYSE:HYH) last released its quarterly earnings data on Wednesday, August 3rd. The company reported $0.45 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.36 by $0.09. Halyard Health had a positive return on equity of 8.91% and a negative net margin of 27.63%. The business had revenue of $400 million for the quarter, compared to analyst estimates of $383.08 million. During the same quarter in the prior year, the firm posted $0.52 EPS. The business’s quarterly revenue was up 2.7% compared to the same quarter last year. Analysts expect that Halyard Health will post $1.82 earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently made changes to their positions in HYH. Nisa Investment Advisors LLC raised its position in shares of Halyard Health by 204.2% in the second quarter. Nisa Investment Advisors LLC now owns 14,897 shares of the company’s stock worth $484,000 after buying an additional 10,000 shares during the period. Gateway Investment Advisers LLC purchased a new position in Halyard Health during the second quarter valued at approximately $439,000. BNP Paribas Arbitrage SA increased its position in Halyard Health by 799.0% in the second quarter. BNP Paribas Arbitrage SA now owns 28,740 shares of the company’s stock valued at $935,000 after buying an additional 25,543 shares in the last quarter. Springbok Capital Management LLC increased its position in Halyard Health by 151.9% in the first quarter. Springbok Capital Management LLC now owns 6,800 shares of the company’s stock valued at $195,000 after buying an additional 4,100 shares in the last quarter. Finally, Nuveen Asset Management LLC increased its position in Halyard Health by 22.2% in the first quarter. Nuveen Asset Management LLC now owns 85,044 shares of the company’s stock valued at $2,443,000 after buying an additional 15,467 shares in the last quarter. Hedge funds and other institutional investors own 82.93% of the company’s stock.
Halyard Health Company Profile
Halyard Health, Inc seeks to advance health and healthcare by preventing infection, eliminating pain and speeding recovery. The Company operates through two segments: Surgical and Infection Prevention (S&IP) and Medical Devices. Its S&IP business provides healthcare supplies and solutions that target the prevention of healthcare associated infections.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Halyard Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.